Position paper
17 Jan 2025
Pharmacy-mediated substitution for biosimilars
Pharmacy-mediated substitution is a framework permitting substitution of medicines at the retail pharmacy without the consent of the prescribing physician. In this paper, IFPMA outlines a set of principles that can guide pharmacy-mediated substitution. While the principles are intended for the awareness of pharmacists, they can also relate to other healthcare providers, regulators, payers, and those involved in formulary and procurement decision-making.
Read more
External study
19 Dec 2024
Global regulatory approaches to post-approval changes in biotherapeutic products
IFPMA worked with Clarivate to study how different countries regulate post-approval changes (PACs) in biotherapeutic products. The research compared PACs guidelines across 21 countries and regions in Latin America (LATAM), Asia-Pacific (APAC), and the Middle East and Africa (MEA) to the World Health Organization (WHO) Guidelines on changes on biotherapeutic products. The findings reveal significant diversity in the level of convergence among countries and with the WHO Reference Guidelines, with a few notable trends.
Read more
Statement
6 Nov 2024
IFPMA-INTERFARMA-FIFARMA statement on the Rio de Janeiro Declaration of the G20 Health Ministers
The innovative pharmaceutical industry, represented by IFPMA, INTERFARMA and FIFARMA reiterates its commitment to the G20 health priorities, reaffirmed in the Rio de Janeiro Declaration.
Read more